Atul Malhotra, Daniel J. Gottlieb, Holger Woehrle, Ellen B. Dennehy, Giulia Calamai, Zhuqing Liu, Sujatro Chakladar, Ronan Grimes, Beverly L. Falcón, Vaishnavi Kundel, ATTAIN-OSA Investigators, Juan José Morales Virgen, Melchor Alpízar Salazar, Hsueh-Yu Li, Pablo Costanzo, Apinya Vutikullird, Thomas Sch uuml rholz, Ryutaro Shirahama, Luis Larrateguy, Gary Soucie, Katharina Lederer, Guixia Wang, Iwao Gohma, Xiaozhen Jiang, John Hudson, Kei Nakamura, Francisco Lopez Maldonado, Cíntia Cercato, Liang-Wen Hang, Thomas Schaum, Ludger Rose, Xiaowei Zhu, Mauricio Waintrub, Maria Arechavaleta Granell, Diego Aizenberg, Jianping Yao, Chu-Kuang Chou, James Maynard, Dirk Weber, Saeko Osawa, Gaylon Kipp, Luis Henrique Canani, Cesar Calvo Vargas, Luis Nevárez, Li Li, Paul Hartley, Yan Yang, Tetsuya Kawano, Klaudia Halova Karoliova, John Parker and 10 more
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Conclusions and Relevance: These results provide evidence for the potential use of oral orforglipron to improve sleep-disordered breathing in adults with moderate to severe OSA and obesity or overweight.
CONCLUSIONS: Daily AIH sessions are safe and well tolerated in persons with MS across a clinically heterogeneous disability range and produce significant improvements in ankle plantarflexion strength and walking endurance.
A. Nehrujee, R. Kalvakota, A. Barry and 11 more — medRxiv
These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.
Stefan Schreiber, Vijay Yajnik, Cenfu Wei and 20 more — Nature Medicine